-
1.发明公开SUBSTITUTED AMINO SIX-MEMBERED SATURATED HETEROCYCLIC FAT USED AS LONG-ACTING DPP-IV INHIBITOR 审中-公开用作长效DPP-IV抑制剂的取代氨基六元饱和杂环脂
公开(公告)号：EP3257857A1
公开(公告)日：2017-12-20
申请号：EP16748717.2
申请日：2016-02-04
申请人： Centaurus BioPharma Co., Ltd. , Chai Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： XU, Xinhe , SHEN, Yu , XIAO, Dengming , LUO, Hong , PENG, Yong , HAN, Yongxin , ZHANG, Aiming , YANG, Ling
IPC分类号： C07D513/14 , C07D487/04 , C07D495/04 , C07D405/04 , A61K31/542 , A61K31/4162 , A61K31/407 , A61K31/4035 , A61P5/50 , A61P3/10
CPC分类号： C07D513/14 , A61K31/4035 , A61K31/407 , A61K31/4162 , A61K31/542 , A61P1/00 , A61P3/04 , A61P7/00 , A61P25/00 , C07D405/04 , C07D487/04 , C07D495/04
摘要： The present application relates to a substituted amino six-membered saturated heteroalicycle represented by formula I as a long-acting DPP-IV inhibitor, a method for preparing the same, a pharmaceutical composition comprising the same, and a use of the same in treating and/or preventing diseases and disorders benefitting from DPP-IV inhibition.
摘要翻译： 本申请涉及作为长效DPP-IV抑制剂的由式I表示的取代氨基六元饱和杂脂环，其制备方法，包含其的药物组合物，以及其用于治疗和 /或预防受益于DPP-IV抑制的疾病和病症。
-
2.发明公开
公开(公告)号：EP3434676A1
公开(公告)日：2019-01-30
申请号：EP17769492.4
申请日：2017-03-27
申请人： Chai Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： WANG, Shulong , CHEN, Kuncheng , LIU, Xijie , HU, Yuandong , LIU, Bo , PENG, Yong , LUO, Hong , HAN, Yongxin , WANG, Shanchun , LIU, Mei , XU, Hongjiang
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P35/02
摘要： The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.
-
公开(公告)号：EP3050880B1
公开(公告)日：2019-06-19
申请号：EP14849754.8
申请日：2014-09-28
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： XIAO, Dengming , ZHU, Yan , HU, Yuandong , WANG, Huting , LI, Jijun , PENG, Yong , ZHANG, Hui , LUO, Hong , KONG, Fansheng , HAN, Yongxin
IPC分类号： C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , A61K31/517 , A61K31/5377 , A61P35/00
-
公开(公告)号：EP3330258A1
公开(公告)日：2018-06-06
申请号：EP16829878.4
申请日：2016-07-29
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHAO, Na , WANG, Shulong , LIU, Xijie , HU, Yuandong , ZHANG, Hui , LUO, Hong , PENG, Yong , HAN, Yongxin , ZHANG, Xiquan , XU, Hongjiang
IPC分类号： C07D251/18 , C07D251/26 , A61K31/53 , A61P35/00
CPC分类号： A61K31/53 , C07D251/18 , C07D251/26
摘要： Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.
-
公开(公告)号：EP3235819A1
公开(公告)日：2017-10-25
申请号：EP15869312.7
申请日：2015-12-15
申请人： Centaurus BioPharma Co., Ltd. , Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHU, Li , XIAO, Dengming , HU, Yuandong , DAI, Liguang , DUAN, Xiaowei , SUN, Yinghui , PENG, Yong , KONG, Fansheng , LUO, Hong , HAN, Yongxin , YANG, Ling , WANG, Shanchun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
摘要： The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.
摘要翻译： 本申请涉及药物化学领域，特别涉及通式（I）所示的吡咯并嘧啶化合物，其立体异构体或其药学上可接受的盐。 本发明还涉及通式（I）代表的吡咯并嘧啶化合物的制备方法，药物组合物和吡咯并嘧啶化合物在治疗由Janus激酶介导的疾病中的用途。
-
公开(公告)号：EP3330263B1
公开(公告)日：2020-11-18
申请号：EP16829888.3
申请日：2016-07-29
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： WANG, Shulong , ZHAO, Na , LIU, Xijie , HU, Yuandong , ZHANG, Hui , LUO, Hong , PENG, Yong , XIAO, Dengming , HAN, Yongxin , ZHANG, Xiquan , TIAN, Xin
IPC分类号： C07D333/24 , C07D409/12 , C07D213/56 , C07D231/12 , C07D409/10 , C07D333/20 , C07C275/42 , A61K31/17 , A61K31/38 , A61K31/381 , A61K31/397 , A61K31/415 , A61K31/4418 , A61K31/4436 , A61K31/4535 , A61P35/02
-
7.发明公开
公开(公告)号：EP3533796A1
公开(公告)日：2019-09-04
申请号：EP17863410.1
申请日：2017-10-27
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHU, Li , HU, Yuandong , WU, Wei , DAI, Liguang , DUAN, Xiaowei , YANG, Yanqing , SUN, Yinghui , HAN, Yongxin , PENG, Yong , KONG, Fansheng , LUO, Hong , YANG, Ling , XU, Hongjiang , GUO, Meng , ZHONG, Zhaobai , WANG, Shanchun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377
摘要： Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.
-
公开(公告)号：EP2952510B1
公开(公告)日：2018-12-26
申请号：EP14746385.5
申请日：2014-01-27
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： XIAO, Dengming , XU, Xinhe , LIU, Xijie , HU, Yuandong , YU, Honghao , LIU, Zhihua , PENG, Yong , SUN, Yinghui , LUO, Hong , KONG, Fansheng , HAN, Yongxin , SUN, Jian
IPC分类号： C07D401/04 , C07D213/74 , C07D401/06 , C07D401/14 , C07D213/73 , C07F9/6558 , A61K31/496 , A61K31/675 , A61K31/4545 , A61K31/5377 , A61K31/444 , A61K31/506 , A61P35/00
CPC分类号： C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K31/675 , C07D213/73 , C07D213/74 , C07D401/04 , C07D401/06 , C07F9/65583
摘要： Disclosed are a 2-aminopyridine derivative having protein kinase inhibition activity, a preparation method and a pharmaceutical composition thereof Also disclosed are uses of the compounds and the pharmaceutical compositions thereof in the preparation of drugs for treating and/or preventing protein kinase-related diseases.
-
9.发明公开QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR 审中-公开CHINAZOLINDERIVAT UND HERSTELLUNGSVERFAHRENDAFÜR
公开(公告)号：EP3050880A1
公开(公告)日：2016-08-03
申请号：EP14849754.8
申请日：2014-09-28
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Centaurus BioPharma Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： XIAO, Dengming , ZHU, Yan , HU, Yuandong , WANG, Huting , LI, Jijun , PENG, Yong , ZHANG, Hui , LUO, Hong , KONG, Fansheng , HAN, Yongxin
IPC分类号： C07D403/12 , C07D401/12 , C07D405/14 , C07D401/14 , A61K31/517 , A61K31/5377 , A61P35/00
CPC分类号： C07D403/12 , A61P35/00 , C07D401/12 , C07D401/14 , C07D405/14
摘要： The present invention relates to a quinazoline derivative shown in formula (I) and a preparation method therefor, a pharmaceutical composition comprising the compound shown in formula (I), and an application of the compound in preparing drugs for curing and preventing tumors. The compound of the present invention can irreversibly prevent EGFR phosphorylation, and effectively depress signal transduction of cancer cells, and accordingly has higher anti-tumor activity in vitro and in vivo.
摘要翻译： 本发明涉及式（I）所示的喹唑啉衍生物及其制备方法，包含式（I）所示化合物的药物组合物和该化合物在制备用于治疗和预防肿瘤的药物中的应用。 本发明的化合物可以不可逆地防止EGFR磷酸化，并有效抑制癌细胞的信号转导，因此在体外和体内具有较高的抗肿瘤活性。
-
公开(公告)号：EP3235819B1
公开(公告)日：2020-11-18
申请号：EP15869312.7
申请日：2015-12-15
申请人： Centaurus BioPharma Co., Ltd. , Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd.
发明人： ZHU, Li , XIAO, Dengming , HU, Yuandong , DAI, Liguang , DUAN, Xiaowei , SUN, Yinghui , PENG, Yong , KONG, Fansheng , LUO, Hong , HAN, Yongxin , YANG, Ling , WANG, Shanchun
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.021 秒)
